LobbyingCoalition To Stop Flu lobbying by quarter
Coalition To Stop Flu's latest lobbying report covers Q2 2026, at $86K. The four quarters Q4 2025–Q3 2026 total $258K. Its first report covers Q4 2022; the issues it reports most are Health Issues and Budget/Appropriations.
Coalition To Stop Flu
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $258K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $86K | 2 |
| Q1 2023 | $86K | 2 |
| Q2 2023 | $86K | 2 |
| Q3 2023 | $86K | 2 |
| Q4 2023 | $86K | 2 |
| Q1 2024 | $96K | 3 |
| Q2 2024 | $86K | 2 |
| Q3 2024 | $86K | 2 |
| Q4 2024 | $86K | 2 |
| Q1 2025 | $86K | 2 |
| Q2 2025 | $86K | 2 |
| Q3 2025 | $86K | 2 |
| Q4 2025 | $86K | 2 |
| Q1 2026 | $86K | 2 |
| Q2 2026 | $86K | 2 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$1M · 31 reports
- Budget and appropriations$270K · 15 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES31 reports
- SENATE31 reports
- Executive Office of the President (EOP)11 reports
- Health & Human Services, Dept of (HHS)4 reports
- Food & Drug Administration (FDA)1 reports
Firms it paid
| Firm | ||
|---|---|---|
| SL Strategies | $540K | 15 quarters |
| DB3 | $470K | 10 quarters |
| Baker Donelson Bearman Caldwell & Berkowitz | $290K | 6 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| MARY MOODY JOHNSON | U.S. Senate Committee on Health, Education, Labor and Pensions | Q2 2026 |
| SARA LOVE RAWLINGS | U.S. Senate Committee on Appropriations | Q2 2026 |
| THOMAS DASCHLE | Former United States Senator | Q4 2025 |
| THOMAS DASCHLE | Former United States Senator | Q3 2023 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 08/17for Q2 | SL Strategies | $36K |
| 07/17for Q2 | DB3 | $50K |
| 05/04for Q1 | SL Strategies | $36K |
| 04/20for Q1 | DB3 | $50K |
| 01/20for Q4 2025 | SL Strategies | $36K |
| 01/20for Q4 2025 | DB3 | $50K |
| 25/11/10for Q3 2025 | SL Strategies | $36K |
| 25/10/20for Q3 2025 | DB3 | $50K |
| 25/07/22for Q2 2025 | SL Strategies | $36K |
| 25/07/18for Q2 2025 | DB3 | $50K |
| 25/04/21for Q1 2025 | DB3 | $50K |
| 25/04/21for Q1 2025 | SL Strategies | $36K |
| 25/02/20for Q4 2024 | SL Strategies | $36K |
| 25/01/21for Q4 2024 | DB3 | $50K |
| 24/10/31for Q3 2024 | SL Strategies | $36K |
| 24/10/21for Q3 2024 | DB3 | $50K |
| 24/07/19for Q2 2024 | DB3 | $50K |
| 24/07/16for Q2 2024 | SL Strategies | $36K |
| 24/05/07for Q1 2024 | SL Strategies | $36K |
| 24/04/20for Q1 2024 | DB3 | $20K |